Real world evidence (RWE) studies generate convincing observational data outside of randomised controlled trials (RCT) to create more awareness on diseases, products, and patient populations. Since RWE can answer questions unaddressed by RCTs, it permits a universal assessment of a drug in a real world context and paves the way to better health outcomes and cost-effectiveness of new health technologies. Despite challenges and barriers that influence access to and the use of RWE data, stakeholders realise that observational studies that are properly designed and conducted can discover unseen facets of diseases that can help them take strategic decisions and deliver better health care. The need of the hour is a change in policy to negate the challenges and barriers in accessing RWE data, facilitating the utilization of the existing goldmine of data in the form of real world information.
展开▼
